36 results
6-K
EX-99.1
ALVO
Alvotech
22 May 24
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
6:30am
levels have been implicated in several chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [3
6-K
EX-99.1
ALVO
Alvotech
21 May 24
Current report (foreign)
9:00am
of adult patients with moderate to severe chronic Ps who are candidates for systemic therapy or phototherapy, and when other systemic therapies … and benefits of treatment with SIMLANDI prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3
6-K
EX-99.1
ALVO
Alvotech
25 Apr 24
Current report (foreign)
12:36pm
implicated in several chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [2]. AVT05
6-K
EX-99.1
ALVO
Alvotech
16 Apr 24
Current report (foreign)
6:30pm
SELARSDI and the reference product Stelara in patients with moderate to severe chronic plaque-type psoriasis. The study was conducted in four … . Consider the risks and benefits of treatment prior to initiating use of SELARSDI in patients with a chronic infection or a history of recurrent
6-K
EX-99.1
8q8iz rphhp
20 Mar 24
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
4:30pm
6-K
EX-99.1
v42gky
23 Feb 24
Current report (foreign)
8:39pm
6-K
EX-99.1
pikhy2l2
10 Jan 24
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
7:00am
6-K
EX-99.1
wxvgk3ur24k tywj9w9
29 Nov 23
Current report (foreign)
7:00am
6-K
EX-99.1
t6rtt0jru
13 Nov 23
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
6:15am
6-K
EX-99.1
zbk65
3 Oct 23
Current report (foreign)
8:51am
6-K
EX-99.8
254jybwel4 t3v1fphg
31 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.1
4dezfk 0tlprxtx
19 May 23
Alvotech Reports Financial Results for First three Months of 2023
11:54am
6-K
EX-99.1
b5nxaqlzq3 7w
4 May 23
Current report (foreign)
7:20am
424B3
0c5l1s3o
21 Sep 22
Prospectus supplement
4:59pm
424B3
w55vb8iwawf
21 Sep 22
Prospectus supplement
4:54pm
F-1/A
jrlze5wtbs
14 Sep 22
Registration statement (foreign) (amended)
4:58pm
F-1/A
8xvtcrh1fizw3bsn
13 Sep 22
Registration statement (foreign) (amended)
5:19pm
6-K
EX-99.3
54vap4i57d4j8 1f
31 Aug 22
Current report (foreign)
5:23pm
F-1/A
otu0y ldh5
27 Jul 22
Registration statement (foreign) (amended)
5:13pm